✨ Free AI Report
Affimed N.V.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Affimed N.V.
Company Research

Affimed N.V.: Business Overview, Financials & Competitive Analysis

Affimed N.V. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage biotech with differentiated bispecific antibody platform carries high binary risk typical of pre-revenue development-stage companies. Affimed operates in a promising immuno-oncology space with proprietary platform technology and strategic partnerships, but faces significant clinical-stage execution risk and severe equity dilution reflected in its collapsed market capitalization. The company's pipeline is.

What is Affimed N.V.'s industry? Affimed N.V. (affimed.com) operates in Biopharmaceuticals - Immuno-Oncology. AskCyborg classifies Affimed N.V. under Biopharmaceuticals - Immuno-Oncology in its company registry.

Affimed N.V. is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's Innate C...

4/ 10Mixed

Cyborg Score thesis

Clinical-stage biotech with differentiated bispecific antibody platform carries high binary risk typical of pre-revenue...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Immuno-Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Affimed N.V. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Affimed N.V.

AskCyborg analysts argue the bull and bear cases for Affimed N.V. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Affimed N.V. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Affimed N.V. Overview

Pro stress-test →

Affimed N.V. is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's Innate Cell Engagers (ICE®), generated from its proprietary ROCK® platform, are bispecific antibodies which target innate immune cells like natural killer (NK) cells and macrophages, to destroy tumor cells.

Strategic Profile

Pro stress-test →

Affimed has three active clinical programs focused on solid tumors and blood cancers, with lead candidate Acimtamig (AFM13) in development for patients with CD30-positive lymphomas. The company has collaborations with Artiva Biotherapeutics, Roivant Sciences Ltd., and Genentech for developing and commercializing novel ICE molecules in oncology.

Competitive Landscape

Pro stress-test →

Affimed competes through strategic partnerships and collaboration agreements with key players like Genentech for NK cell engager-based immunotherapeutics to treat multiple cancers. The company's main competition includes established NK cell therapy players (Artiva Biotherapeutics), bispecific antibody developers, and conventional checkpoint inhibitor producers. Affimed's differentiation rests on its tetravalent bispecific design and innate immune focus rather than adaptive T-cell approaches.

Industry Context

Affimed N.V. operates in Biopharmaceuticals - Immuno-Oncology.

Key facts

Founded: 2000 · Headquarters: Mannheim, Germany · Employees: 76 · Market cap: $2.975M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Affimed N.V..

  • Platform-driven approach: Affimed's proprietary ROCK® platform systematically generates multiple innate cell engager candidates with consistent development timelines
  • Strategic alliances reduce execution risk: Collaborations with established pharma (Genentech, Roivant) and emerging immunotherapy players (Artiva) provide clinical, commercial, and financial support
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • 2024Lead programs AFM13 and AFM24 advanced with encouraging clinical data in Hodgkin Lymphoma and NSCLC
  • 2025Company maintaining clinical operations and partnerships despite severe market valuation challenges
  • +1 moreTrack every material event for Affimed N.V. as it happens. Explore monitoring →
Get alerted when Affimed N.V. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

AlloNKAllogeneic NK cell therapy combined with AFM13 in clinical development→PD-L1 inhibitorsAtezolizumab checkpoint inhibitor combined with AFM24 in Phase IIa studies→NK cell therapiesCompeting NK cell engagement and adoptive cell therapy approaches→

Compare Affimed N.V. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Affimed N.V. operates in Biopharmaceuticals - Immuno-Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Immuno-Oncology research →
NEW · MCP server

Ask your AI assistant about Affimed N.V.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Affimed N.V. and its top competitor on Cyborg Score”
“What did Affimed N.V. do this quarter?”
“Is Affimed N.V. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Affimed N.V. do?+
Affimed N.V. is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's Innate C...
What is Affimed N.V.'s Cyborg Score?+
Affimed N.V. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Affimed N.V.'s main competitors?+
Named competitors include AlloNK, PD-L1 inhibitors, NK cell therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Affimed N.V. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Affimed N.V. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Affimed N.V. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Immuno-Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Ikena Oncology